Dr. Kennen MacKay is Managing Director and Co-Head of RBC Capital Markets' Biotechnology Equity Research team. Kennen covers a range of Large & SMid-Cap biotechnology companies across a range of therapeutic indications & modalities: from small molecule precision medicines to antibody/protein products, to gene therapies, gene editing, & cellular therapeutics, Kennen’s interests span all things biotech. Kennen previously covered the biotechnology sector at Credit Suisse and Citigroup, and held biotechnology roles in non-profit and laboratory research settings prior to his career on Wall St. Kennen received his PhD in Biochemistry and Molecular Biology from UCLA, and his BA in Biochemistry from Colorado College.